DE-PRESCRIBING MEDICATIONS IN OLDER ADULTS WITH DEMENTIA
Dr Daniel Hoyle
Senior Lecturer, Therapeutics and Pharmacy Practice
School of Pharmacy and Pharmacology,
University of Tasmania, Australia
RESEARCHER PROFILE
Filmed in Hobart, Tasmania, Australia | January 2025
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
He earned his PhD from the University of Tasmania in 2020, where his doctoral research examined the clinical and economic outcomes of psychotropic deprescribing within the multidisciplinary “Reducing Use of Sedatives” project implemented across 150 Australian aged care homes. This research has received several accolades, including First Place in the International Psychogeriatric Association Junior Research Awards in 2019.
Currently, Dr. Hoyle leads several projects, including research aimed at improving anticoagulant use in older individuals with dementia and atrial fibrillation using national primary care provider datasets, and the implementation of a hospital-based antipsychotic stewardship program for patients with dementia and/or delirium.
A current project is Geriatric Antipsychotic Stewardship (GApS) Program for Behavioural and Psychological Symptoms of Dementia and Delirium. This program is funded by the Royal Hobart Hospital Research Foundation through an Incubator Grant.
Additionally, Dr. Hoyle serves as an investigator within an educational intervention aimed at improving anticholinergic prescribing in hospitals. Dr. Hoyle is a guest editor with Pharmacy MDPI and holds elected positions on the Australian Deprescribing Network Executive Committee and the Pharmaceutical Society of Australia’s Tasmanian Branch Committee.
https://orcid.org/0000-0003-2867-3736
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
-
Novel silk-based biomaterials for tissue engineering and regenerative medicine
Dr Jelena Rnjak-Kovacina is a Scientia Associate Professor and ARC Future Fellow leading a multidisciplinary group at the Graduate School of Biomedical Engineering, UNSW Sydney in Australia.
Her research interests are at the interface of biology and engineering, focusing on the development of biomimetic materials that direct cellular interactions for enhanced vascularisation and for the treatment of cardiovascular disease. In particular, she develops novel silk-based biomaterials and investigates how biomaterial properties translate to biological outcomes.
